Cogent Biosciences, Inc. - Common Stock, $0.001 par value (COGT)

Historical Holders from Q4 2020 to Q3 2025

Symbol
COGT on Nasdaq
Type / Class
Equity / Common Stock, $0.001 par value
Shares outstanding
160M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
159M
Holdings value
$2.29B
% of all portfolios
0.011%
Grand Portfolio weight change
+0.001%
Number of holders
190
Number of buys
122
Number of sells
-70
Average Value change %
0%
Average buys %
+0.003%
Average sells %
-0.003%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cogent Biosciences, Inc. - Common Stock, $0.001 par value (COGT)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% $81.4M 16.6M FMR LLC 31 Dec 2024
Fairmount Funds Management LLC 9.9% 0% $224M $21.9M 15.9M +10.8% Fairmount Funds Management LLC 13 Nov 2025
Commodore Capital LP 7.2% +28.3% $147M $54.6M 10.2M +59.3% Commodore Capital LP 30 Sep 2025
Flynn James E 6.49% $65M 9.05M Deerfield Mgmt, L.P. 07 Jul 2025
Kynam Capital Management, LP 5.54% $113M 7.89M Kynam Capital Management, LP 30 Sep 2025
TCG Crossover GP I, LLC 4.8% $97.6M 6.8M TCG Crossover GP I, LLC 30 Sep 2025
Point72 Asset Management, L.P. 4% -52.2% $82.6M -$60.8M 5.75M -42.4% Point72 Asset Management, L.P. 30 Sep 2025
Venrock Healthcare Capital Partners II, L.P. 4.2% -26.7% $44.5M -$15.8M 4.76M -26.2% Venrock Healthcare Capital Partners II, L.P. 30 Jun 2025
Paradigm Biocapital Advisors LP 2.3% -75.6% $45.3M -$103M 3.16M -69.5% Paradigm BioCapital Advisors LP 30 Sep 2025

Institutional Holders of Cogent Biosciences, Inc. - Common Stock, $0.001 par value (COGT)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 159M $2.29B +$378M $14.36 190
2025 Q2 136M $973M +$19M $7.18 175
2025 Q1 133M $800M +$57.9M $5.99 182
2024 Q4 122M $949M -$21.7M $7.80 173
2024 Q3 122M $1.32B +$471K $10.80 160
2024 Q2 121M $1.02B +$107M $8.43 146
2024 Q1 109M $734M +$128M $6.72 144
2023 Q4 90.8M $534M -$45.4M $5.88 141
2023 Q3 90.9M $886M +$20.5M $9.75 134
2023 Q2 88.5M $1.05B +$159M $11.84 134
2023 Q1 75.2M $810M +$3.23M $10.79 133
2022 Q4 74.7M $863M -$1.8M $11.56 133
2022 Q3 73.7M $1.1B +$70.8M $14.92 129
2022 Q2 70.1M $632M +$209M $9.02 107
2022 Q1 47.2M $354M -$5.66M $7.49 81
2021 Q4 44.9M $385M +$41.8M $8.58 80
2021 Q3 36.8M $310M +$4.14M $8.41 71
2021 Q2 35M $284M +$12.9M $8.11 65
2021 Q1 34.4M $303M +$9.82M $8.78 65
2020 Q4 33.5M $376M +$318M $11.23 67